PA2G4 promotes the metastasis of hepatocellular carcinoma by stabilizing FYN mRNA in a YTHDF2-dependent manner.
FYN
HCC
PA2G4
YTHDF2
m6A
Journal
Cell & bioscience
ISSN: 2045-3701
Titre abrégé: Cell Biosci
Pays: England
ID NLM: 101561195
Informations de publication
Date de publication:
07 May 2022
07 May 2022
Historique:
received:
17
11
2021
accepted:
16
04
2022
entrez:
7
5
2022
pubmed:
8
5
2022
medline:
8
5
2022
Statut:
epublish
Résumé
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide with high mortality. Advanced stage upon diagnosis and cancer metastasis are the main reasons for the dismal prognosis of HCC in large part. The role of proliferation associated protein 2G4 (PA2G4) in tumorigenesis and cancer progression has been widely investigated in various cancers. However, whether and how PA2G4 participates in HCC metastasis is still underexplored. We found that the mRNA and protein levels of PA2G4 were higher in HCC samples than in normal liver tissues, and high expression of PA2G4 in HCC was correlated with a poor prognosis, by an integrative analysis of immunohistochemistry (IHC), western blot and bioinformatic approach. Moreover, the expression of PA2G4 was elevated in HCC patients with metastases than those metastasis-free. Cell migration, invasion, phalloidin staining and western blot analyses demonstrated that PA2G4 promoted epithelial to mesenchymal transition (EMT) of HCC cells in vitro. And a lung metastasis animal model exhibited that PA2G4 enhanced metastatic ability of HCC cells in vivo. RNA-sequencing combined with dual luciferase reporter assay and evaluation of mRNA half-time indicated that PA2G4 increased FYN expression by stabilizing its mRNA transcript. Recovering the impaired FYN level induced by PA2G4 knockdown rescued the impeded cell mobilities. Furthermore, endogenous immunoprecipitation (IP) and in-situ immunofluorescence (IF) showed that YTH N6-methyladenosine RNA binding protein 2 (YTHDF2) was the endogenous binding patterner of PA2G4. In addition, RNA binding protein immunoprecipitation (RIP) and anti- N6-methyladenosine immunoprecipitation (MeRIP) assays demonstrated that FYN mRNA was N6-methyladenosine (m6A) modified and bound with PA2G4, as well as YTHDF2. Moreover, the m6A catalytic ability of YTHDF2 was found indispensable for the regulation of FYN by PA2G4. At last, the correlation of expression levels between PA2G4 and FYN in HCC tissues was verified by IHC and western blot analysis. These results indicate that PA2G4 plays a pro-metastatic role by increasing FYN expression through binding with YTHDF2 in HCC. PA2G4 may become a reliable prognostic marker or therapeutic target for HCC patients.
Sections du résumé
BACKGROUND
BACKGROUND
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide with high mortality. Advanced stage upon diagnosis and cancer metastasis are the main reasons for the dismal prognosis of HCC in large part. The role of proliferation associated protein 2G4 (PA2G4) in tumorigenesis and cancer progression has been widely investigated in various cancers. However, whether and how PA2G4 participates in HCC metastasis is still underexplored.
RESULTS
RESULTS
We found that the mRNA and protein levels of PA2G4 were higher in HCC samples than in normal liver tissues, and high expression of PA2G4 in HCC was correlated with a poor prognosis, by an integrative analysis of immunohistochemistry (IHC), western blot and bioinformatic approach. Moreover, the expression of PA2G4 was elevated in HCC patients with metastases than those metastasis-free. Cell migration, invasion, phalloidin staining and western blot analyses demonstrated that PA2G4 promoted epithelial to mesenchymal transition (EMT) of HCC cells in vitro. And a lung metastasis animal model exhibited that PA2G4 enhanced metastatic ability of HCC cells in vivo. RNA-sequencing combined with dual luciferase reporter assay and evaluation of mRNA half-time indicated that PA2G4 increased FYN expression by stabilizing its mRNA transcript. Recovering the impaired FYN level induced by PA2G4 knockdown rescued the impeded cell mobilities. Furthermore, endogenous immunoprecipitation (IP) and in-situ immunofluorescence (IF) showed that YTH N6-methyladenosine RNA binding protein 2 (YTHDF2) was the endogenous binding patterner of PA2G4. In addition, RNA binding protein immunoprecipitation (RIP) and anti- N6-methyladenosine immunoprecipitation (MeRIP) assays demonstrated that FYN mRNA was N6-methyladenosine (m6A) modified and bound with PA2G4, as well as YTHDF2. Moreover, the m6A catalytic ability of YTHDF2 was found indispensable for the regulation of FYN by PA2G4. At last, the correlation of expression levels between PA2G4 and FYN in HCC tissues was verified by IHC and western blot analysis.
CONCLUSIONS
CONCLUSIONS
These results indicate that PA2G4 plays a pro-metastatic role by increasing FYN expression through binding with YTHDF2 in HCC. PA2G4 may become a reliable prognostic marker or therapeutic target for HCC patients.
Identifiants
pubmed: 35526051
doi: 10.1186/s13578-022-00788-5
pii: 10.1186/s13578-022-00788-5
pmc: PMC9080163
doi:
Types de publication
Journal Article
Langues
eng
Pagination
55Subventions
Organisme : National Natural Science Foundation of China
ID : 81372327
Organisme : National Natural Science Foundation of China
ID : 81572427
Organisme : National Natural Science Foundation of China
ID : 81874189
Organisme : the State Key Project on Infection Disease of China
ID : 2018ZX10723204-003-003
Organisme : the National Key Research and Development Program of China
ID : 2018YFA0208904
Organisme : the Major Technological Innovation Projects of Hubei Province
ID : 2018ACA137
Informations de copyright
© 2022. The Author(s).
Références
EMBO J. 2021 Feb 1;40(3):e105977
pubmed: 33470439
Oncogene. 2014 Jul 17;33(29):3839-50
pubmed: 23975429
Clin Cancer Res. 2016 Jul 1;22(13):3320-7
pubmed: 26813358
Mol Immunol. 2015 Oct;67(2 Pt B):540-51
pubmed: 26256794
Oncol Lett. 2021 Jul;22(1):538
pubmed: 34084217
J Cell Physiol. 2019 Aug;234(10):17612-17621
pubmed: 30793766
Nature. 2015 Oct 22;526(7574):591-4
pubmed: 26458103
Mol Cancer. 2019 Nov 18;18(1):163
pubmed: 31735169
Cancer Res. 2009 Sep 1;69(17):6889-98
pubmed: 19690143
Mol Biol Rep. 2013 May;40(5):3799-805
pubmed: 23283744
Cell. 2016 Jun 30;166(1):21-45
pubmed: 27368099
Nat Rev Dis Primers. 2021 Jan 21;7(1):6
pubmed: 33479224
Oncogene. 2020 Jun;39(23):4507-4518
pubmed: 32366907
Neuro Oncol. 2020 Jun 9;22(6):806-818
pubmed: 31950181
Nature. 2021 Jan;589(7842):448-455
pubmed: 33328637
Hepatology. 2021 Jul;74(1):214-232
pubmed: 33615520
Cancer Discov. 2021 Feb;11(2):480-499
pubmed: 33023892
Proc Natl Acad Sci U S A. 2005 Jul 12;102(28):9890-5
pubmed: 15994225
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102
pubmed: 28407145
Oncol Rep. 2013 Mar;29(3):1161-6
pubmed: 23242156
Surg Oncol. 2020 Jun;33:108-117
pubmed: 32561075
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
Int J Cancer. 2016 Sep 15;139(6):1202-8
pubmed: 27130196
Mol Cell Endocrinol. 2015 Aug 15;411:75-85
pubmed: 25917452
Cancer Res. 2019 Nov 1;79(21):5652-5667
pubmed: 31501192
Cancer. 2010 Apr 1;116(7):1629-37
pubmed: 20151426
Front Oncol. 2021 May 10;11:652768
pubmed: 34041022
Oncogene. 2020 May;39(21):4183-4197
pubmed: 32291412
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Gastroenterology. 2019 Jan;156(2):477-491.e1
pubmed: 30367835
Nat Commun. 2016 Aug 25;7:12626
pubmed: 27558897
Cancer Cell Int. 2020 Jun 18;20:256
pubmed: 32565740
Tumour Biol. 2015 Nov;36(11):8325-31
pubmed: 26008146
R Soc Open Sci. 2018 Dec 5;5(12):181006
pubmed: 30662724
Cancer Lett. 2019 Feb 1;442:252-261
pubmed: 30423408
Nucleic Acids Res. 2016 Jun 2;44(10):e91
pubmed: 26896799
Mol Carcinog. 2021 Apr;60(4):252-264
pubmed: 33634940
Virchows Arch. 2020 Aug;477(2):279-289
pubmed: 32086588
Open Biol. 2016 Apr;6(4):160003
pubmed: 27249342
Cell Death Dis. 2020 Aug 7;11(8):652
pubmed: 32811808
Mol Cancer. 2019 Nov 21;18(1):166
pubmed: 31752867
Eur Rev Med Pharmacol Sci. 2020 Jan;24(1):109-121
pubmed: 31957823
Nat Commun. 2020 Feb 7;11(1):776
pubmed: 32034140
Appl Immunohistochem Mol Morphol. 2021 Aug 1;29(7):513-518
pubmed: 33605574
BMC Cancer. 2012 Oct 30;12:499
pubmed: 23110497
BMJ. 2020 Oct 26;371:m3544
pubmed: 33106289
Genet Mol Res. 2015 May 22;14(2):5496-500
pubmed: 26125746
Transl Oncol. 2020 Nov;13(11):100841
pubmed: 32763503
Nat Rev Mol Cell Biol. 2020 Jun;21(6):341-352
pubmed: 32300252
J Biol Chem. 2020 Nov 20;295(47):16100-16112
pubmed: 32952126
Nature. 2014 Jan 2;505(7481):117-20
pubmed: 24284625
Mol Cell Biochem. 2014 Nov;396(1-2):175-85
pubmed: 25081333
Hepatology. 2014 Nov;60(5):1620-36
pubmed: 24954480
Cytogenet Cell Genet. 1997;78(1):31-5
pubmed: 9345902